Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII

Background and Objective Emicizumab is a monoclonal antibody that bridges activated coagulation factor IX and factor X to restore effective hemostasis in persons with hemophilia A. It is indicated for routine prophylaxis of bleeding episodes in persons with hemophilia A. The aim of the present study...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical pharmacokinetics 2021-07, Vol.60 (7), p.931-941
Hauptverfasser:	Jonsson, Fredrik, Schmitt, Christophe, Petry, Claire, Mercier, Francois, Frey, Nicolas, Retout, Sylvie
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Bispecific Antibodies, Monoclonal, Humanized Bioavailability Disease prevention Factor VIII Hemophilia Hemophilia A - complications Hemophilia A - drug therapy Humans Internal Medicine Life Sciences & Biomedicine Medicine Medicine & Public Health Monoclonal antibodies Original Original Research Article Pharmacokinetics Pharmacology & Pharmacy Pharmacology/Toxicology Pharmacotherapy Population Science & Technology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!